Brooks announces the acquisition of Trans-Hit Biomarkers

Brooks Automation, Inc. (Nasdaq: BRKS) today announced that it has acquired Trans-Hit Biomarkers Inc. (THB), a worldwide biospecimen procurement service provider based in Montreal Canada. THB has an extensive collection capability for biospecimens and clinical samples through a worldwide partner network of clinical sites and biobanks. THB is enabled by a team with an extensive background in biomedical research that advises biopharma and diagnostic clients on the best solutions to design, organize and conduct sample collections in various fields including oncology and infectious diseases.

Steve Schwartz, president and CEO of Brooks commented, “With a decade of experience solving customers’ research needs with fit-for-purpose biospecimens, THB is a great addition to our life sciences business. Our combined strength in biospecimen procurement, sample management, and genomic analytical services will add value to our customers, which we believe will provide another growth vector to Brooks Life Sciences Services business.”

Dr. Pascal Puchois, the founder and Chief Executive Officer of THB, will continue to lead the business as part of Brooks Life Sciences. The Company expects the acquisition to be modestly accretive to earnings immediately. Specific terms of the acquisition were not disclosed. – PRNewswire